Travere Therapeutics (TVTX) announced its intention to offer, subject to market and other conditions, $400M aggregate principal amount of convertible senior notes due 2032 in an underwritten offering. Travere intends to use a portion of the net proceeds from the offering to repurchase a portion of its currently outstanding convertible notes. J.P. Morgan, Jefferies, and Leerink Partners are acting as joint book-running managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Edward Nash Reiterates Buy on Travere, Maintaining $56 Price Target Amid Strong Filspari Momentum and Expanding Renal Franchise
- Travere Therapeutics price target raised to $60 from $45 at TD Cowen
- Travere Therapeutics price target raised to $55 from $53 at Wedbush
- Travere Therapeutics price target raised to $59 from $53 at Citi
- Travere Therapeutics price target raised to $57 from $47 at H.C. Wainwright